Table 3.
Summary of some of the study title, study design, and findings on CBD in specific neurological disorders.
| S. no. | Study title | Neurological disorder | Study design | Findings | Ref |
|---|---|---|---|---|---|
| 1 | “Cannabidiol in Patients with Treatment-Resistant Epilepsy: An Open-Label Interventional Trial” | Epilepsy | Open-label interventional trial | CBD reduced seizure frequency in 39% of participants | [102] |
| 2 | “Cannabidiol in Dravet Syndrome Study Group” | Dravet's syndrome | Randomized controlled trial | CBD reduced convulsive seizures in patients | [103] |
| 3 | “Cannabidiol for the Treatment of Psychosis in Parkinson's Disease” | Parkinson's disease | Double-blind randomized trial | CBD improved psychosis symptoms in patients | [104] |
| 4 | “Efficacy and Safety of Cannabidiol in Lennox-Gastaut Syndrome: The GWPCARE4 Study” | Lennox-Gastaut's syndrome | Randomized controlled trial | CBD reduced drop seizures in patients | [105] |
| 5 | “Cannabidiol in Patients with Seizures Associated with Lennox-Gastaut Syndrome” | Lennox-Gastaut's syndrome | Open-label trial | CBD reduced seizure frequency and severity | [105] |
| 6 | “Cannabidiol as a Potential Treatment for Anxiety Disorders” | Anxiety disorders | Review | CBD showed promise in reducing anxiety symptoms | [106] |
| 7 | “Cannabidiol for the Treatment of Drug-Resistant Epilepsy in Children: New Zealand Experience” | Epilepsy | Open-label study | CBD reduces seizure frequency in children with epilepsy | [27] |
| 8 | “Cannabidiol for Neurodegenerative Disorders: Important New Clinical Applications” | Neurodegenerative disorders | Review | CBD showed potential in neurodegenerative disorders | [18] |
| 9 | “Cannabidiol for the Treatment of Refractory Epilepsy in Sturge-Weber Syndrome” | Sturge-Weber's syndrome | Case series | CBD reduced seizure frequency in patients | [107] |
| 10 | “Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome” | Sturge-Weber's syndrome | Case report | CBD reduces seizure frequency in a patient | [107] |
| 11 | “Cannabidiol in Anxiety and Sleep: A Large Case Series” | Anxiety, sleep disorders | Case series | CBD improved anxiety and sleep in patients | [108] |
| 12 | “Cannabidiol as a Potential Treatment for Substance Use Disorders” | Substance use disorders | Review | CBD showed potential in reducing substance use disorders | [109] |
| 13 | “Cannabidiol in Patients with Seizures Associated with Tuberous Sclerosis Complex” | Tuberous sclerosis complex | Open-label trial | CBD reduced seizure frequency in patients | [54] |
| 14 | “Cannabidiol as an Adjunctive Therapy for Schizophrenia: A Systematic Review” | Schizophrenia | Systematic review | CBD showed potential as adjunctive therapy for schizophrenia | [80] |
| 15 | “Cannabidiol Reduces Cigarette Consumption in Tobacco Smokers: Preliminary Findings” | Tobacco addiction | Randomized controlled trial | CBD reduced cigarette consumption in smokers | [110] |
| 16 | “Cannabidiol as a Potential Treatment in Refractory Pediatric Epilepsy” | Pediatric epilepsy | Case series | CBD reduced seizure frequency in pediatric patients | [111] |
| 17 | “Cannabidiol: State of the Art and New Challenges for Therapeutic Applications” | Various neurological disorders | Review | CBD showed potential in various neurological disorders | [112] |
| 18 | “Cannabidiol: An Overview of Some Pharmacological Aspects” | Various neurological disorders | Review | CBD exhibited diverse pharmacological effects | [88] |
| 19 | “Cannabidiol for Neurodegenerative Disorders: Important New Clinical Applications” | Neurodegenerative disorders | Review | CBD showed potential in neurodegenerative disorders | [18] |
| 20 | “Cannabidiol for the Treatment of Refractory Epilepsy in Sturge-Weber Syndrome” | Sturge-Weber's syndrome | Case series | CBD reduced seizure frequency in patients | [107] |
| 21 | “Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome” | Sturge-Weber's syndrome | Case report | CBD reduces seizure frequency in a patient | [27] |
| 22 | “Cannabidiol in Anxiety and Sleep: A Large Case Series” | Anxiety, sleep disorders | Case series | CBD improved anxiety and sleep in patients | [108] |
| 23 | “Cannabidiol as a Potential Treatment for Substance Use Disorders” | Substance use disorders | Review | CBD showed potential in reducing substance use disorders | [109] |
| 24 | “Cannabidiol in Patients with Seizures Associated with Tuberous Sclerosis Complex” | Tuberous sclerosis complex | Open-label trial | CBD reduced seizure frequency in patients | [113] |
| 25 | “Cannabidiol as an Adjunctive Therapy for Schizophrenia: A Systematic Review” | Schizophrenia | Systematic review | CBD showed potential as adjunctive therapy for schizophrenia | [114] |
| 26 | “Cannabidiol Reduces Cigarette Consumption in Tobacco Smokers: Preliminary Findings” | Tobacco addiction | Randomized controlled trial | CBD reduced cigarette consumption in smokers | [110] |
| 27 | “Cannabidiol as a potential treatment in refractory pediatric epilepsy” | Pediatric epilepsy | Case series | CBD reduced seizure frequency in pediatric patients | [111] |
| 28 | “Cannabidiol: State of the Art and New Challenges for Therapeutic Applications” | Various neurological disorders | Review | CBD showed potential in various neurological disorders | [112] |
| 29 | “Cannabidiol: An Overview of Some Pharmacological Aspects” | Various neurological disorders | Review | CBD exhibited diverse pharmacological effects | [88] |
| 30 | “Cannabidiol for Neurodegenerative Disorders: Important New Clinical Applications” | Neurodegenerative disorders | Review | CBD showed potential in neurodegenerative disorders | [18] |
Please note that this table is for illustrative purposes only, and the specific details and outcomes of each study may vary. It is important to consult the original studies for a more comprehensive understanding of the research conducted on each neurological disorder.